Boston Scientific Co. (NYSE:BSX) CEO Sells $13,775,817.51 in Stock

Boston Scientific Co. (NYSE:BSX) CEO Michael F. Mahoney sold 162,777 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Boston Scientific Price Performance

Boston Scientific stock opened at $86.70 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The business has a 50-day simple moving average of $80.48 and a 200 day simple moving average of $76.16. The stock has a market cap of $127.20 billion, a price-to-earnings ratio of 72.44, a PEG ratio of 2.78 and a beta of 0.80. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $86.99.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The firm had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same quarter last year, the company posted $0.53 EPS. The business’s quarterly revenue was up 14.5% on a year-over-year basis. On average, research analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Institutional Trading of Boston Scientific

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sierra Summit Advisors LLC purchased a new stake in shares of Boston Scientific in the 4th quarter valued at $8,038,000. BI Asset Management Fondsmaeglerselskab A S lifted its position in Boston Scientific by 225.6% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after purchasing an additional 73,219 shares during the last quarter. BDF Gestion purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $3,570,000. Tlwm bought a new position in shares of Boston Scientific in the first quarter worth approximately $927,000. Finally, LRI Investments LLC purchased a new position in shares of Boston Scientific in the first quarter worth $139,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of a number of research reports. BTIG Research upped their target price on Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research note on Thursday, July 25th. Needham & Company LLC boosted their price target on shares of Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. TD Cowen increased their price objective on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Finally, JPMorgan Chase & Co. boosted their target price on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $87.60.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.